NCT06328400View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

May 6, 2024

Study Completion Date

May 6, 2024

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

Deuremidevir Hydrobromide for Suspension

Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day

DRUG

Deuremidevir Hydrobromide for Suspension Placebo

Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day

Trial Locations (1)

201900

Hushan Hospital Fudan university, Shanghai

All Listed Sponsors
lead

Vigonvita Life Sciences

INDUSTRY

NCT06328400 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension | Biotech Hunter | Biotech Hunter